Immunovaccine and Pfenex Report Positive Results From Single Dose Anthrax Vaccine Studies

Data demonstrates 100% protection against a lethal anthrax challenge in animals after vaccination with as little as 0.33 microgram of mutant recombinant Protective Antigen; Dose response observed in the first 28 days following vaccination April 1, 2014 Immunovaccine Inc. and Pfenex Inc. today announced positive results from anthrax challenge studies in rabbits using Pfenex’s mutant recombinant Protective Antigen (mrPA) formulated …